HC Wainwright Has Strong Forecast for VTYX FY2024 Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Ventyx Biosciences in a research note issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($2.18) per share for the year, up from their previous forecast of ($2.19). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q1 2025 earnings at ($0.71) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($1.98) EPS and FY2028 earnings at ($1.56) EPS.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Stock Up 6.9 %

VTYX opened at $2.02 on Friday. The firm has a market cap of $142.83 million, a price-to-earnings ratio of -0.86 and a beta of 0.55. Ventyx Biosciences has a 52 week low of $1.67 and a 52 week high of $11.48. The business’s 50 day moving average is $2.27 and its two-hundred day moving average is $2.27.

Institutional Trading of Ventyx Biosciences

Institutional investors have recently modified their holdings of the business. Palumbo Wealth Management LLC purchased a new stake in shares of Ventyx Biosciences in the third quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Ventyx Biosciences in the third quarter valued at approximately $42,000. The Manufacturers Life Insurance Company boosted its stake in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after buying an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ventyx Biosciences in the second quarter valued at approximately $58,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider John Nuss sold 21,119 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $2.36, for a total value of $49,840.84. Following the transaction, the insider now owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. The trade was a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sheila Gujrathi bought 130,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $2.31 per share, for a total transaction of $300,300.00. Following the acquisition, the director now owns 130,000 shares of the company’s stock, valued at approximately $300,300. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 630,000 shares of company stock valued at $1,262,415. Company insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.